

U.S. Application No.: 09/985,699
Attorney Ref. No.: 068800-0284057

I. AMENDMENT


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-17. (Canceled)

18. (Previously presented) A method for the depletion of serum amyloid P component (SAP) from the plasma of a subject in need of such treatment, which comprises:

(a) administering to the subject a therapeutically effective amount of a D-proline of the formula (R)-1-[6-(R)-2-Carboxypyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or mono- or diester thereof, wherein R is the group



(b) binding of at least two ligands of said D-proline by ligand binding sites of SAP proteins in the plasma;

(c) forming thereby a complex between said D-proline and a plurality of SAP proteins, wherein the complex is abnormal to the subject; and


(d) causing the complex to be identified by the physiological mechanisms of the subject and cleared from the plasma; and

(e) monitoring the clearance of SAP from the subject's plasma.

19-23. (Canceled)

24. (Currently amended) A method for the depletion of a SAP from the plasma of a subject in need of such treatment, which comprises administering to the subject a therapeutically effective amount of D-proline of the formula (R)-1-[6-(R)-2-Carboxypyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or mono- or diester thereof, wherein R is the group

U.S. Application No.: 09/985,699
Attorney Ref. No.: 068800-0284057



and monitoring the clearance of the disease-associated protein population SAP from the subject's plasma.

25-47. (Canceled)

48. (Previously presented) The method of claim 18, wherein said D-proline is administered orally with a dosage of 50 to 500 mg/per day.

49. (Previously presented) The method of claim 18, wherein said D-proline is administered by injection with a dosage of 0.05 to 6 mg/kg/day.

50. (Previously presented) The method of claim 49, wherein said D-proline is administered by injection with a dosage of 0.1 to 6 mg/kg/day.

51. (Previously presented) The method of claim 50, wherein said D-proline is administered by injection with a dosage of 0.25 to 6 mg/kg/day.

52. (Previously presented) The method of claim 24, wherein said D-proline is administered orally with a dosage of 50 to 500 mg/per day.

53. (Previously presented) The method of claim 24, wherein said D-proline is administered by injection with a dosage of 0.05 to 6 mg/kg/day.

54. (Previously presented) The method of claim 53, wherein said D-proline is administered by injection with a dosage of 0.1 to 6 mg/kg/day.

55. (Previously presented) The method of claim 54, wherein said D-proline is administered by injection with a dosage of 0.25 to 6 mg/kg/day.